Tests dapagliflozin in people with lupus kidney disease and chronic kidney disease
Tests dapagliflozin added to standard care in adults with lupus nephritis and kidney disease.
Plain-language title generated from the registry record
Registry title: SGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Kidney Disease
Key facts
- Where
- Hong Kong, Hong KongSee the site
- Phase
- Phase 2
Where in Hong Kong
- Queen Mary HospitalHong Kong, Hong KongTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The University of Hong Kong
- Trial code
- NCT06155604
- Record updated
- 16 December 2024
- Original description
Lupus nephritis (LN) is a common manifestation in patients with systemic lupus erythematosus (SLE), and is an important cause of acute kidney injury and chronic kidney disease (CKD). Although the standard-of-care treatments for active severe LN are effective, a substantial proportion of LN patients still develop CKD and eventually end-stage kidney disease (ESKD).Read full original descriptionShow less
A Randomized Controlled Trial on SGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Kidney Disease
Lupus nephritis (LN) is a common manifestation in patients with systemic lupus erythematosus (SLE), and is an important cause of acute kidney injury and chronic kidney disease (CKD). Although the standard-of-care treatments for active severe LN are effective, a substantial proportion of LN patients still develop CKD and eventually end-stage kidney disease (ESKD).
Cardiovascular complications are common and is a leading cause of death in SLE and LN patients. It is well recognized that LN patients had multiple risk factors for cardiovascular complications such as diabetes mellitus (DM), dyslipidaemia and vascular inflammation. Sodium-glucose co-transporter 2 (SGLT2) inhibitor are initially developed as an oral anti-diabetic agent and has shown to be effective in glycaemic control, has benefits in lipid metabolism, cardiovascular and renal outcomes, and also well tolerated by patients. Various trials have also demonstrated the benefits of SGLT2 inhibitor in the reduction of CKD, ESKD, and renal or cardiovascular death. However, the effect of SGLT2 inhibitor in LN remains unclear.
The purpose of this study is to investigate the effect of SGLT2 on renal outcomes in LN patients with CKD, as well as the side effects, metabolic profiles, immunological functions and disease stability.
Inclusion: Patients with biopsy-proven Class III or IV or V LN according to the ISN/RPS 2003 classification; Patients with CKD (eGFR 15-60mL/min); Patients in quiescent disease (defined as SLEDAI score <4 with no points in the renal domain); Patients on a stable dose of prednisolone (PRED 5-7.5 mg/D) alone or in combination with MMF (<=1.5 g/D) or AZA (<=150 mg/D) in the past 3 months.
Exclusion: Patients with stage 5 CKD or ESKD on renal replacement therapy; Patients with biopsy-proven glomerulonephritis other than LN or hereditary kidney diseases; Patients with type 1 diabetes mellitus (DM); Patients with frequent urinary tract infections; Patients with history of ketoacidosis.